Loading patent…
AssigneesInstytut Chemii Bioorganicznej Pan, Uniwersytet Medyczny Im.Karola Marcinkowskiego, Bioinfobank Sp.Z O.O.
InventorsJan Barciszewski, Miroslawa Barciszewska, Leszek Rychlewski, Eliza Wyszko, Iwona Gawronska, Ryszard Zukiel, Katarzyna Rolle, Stanisaw Nowak
Estimating the term…
The subject matters of this invention are a sequence of double-stranded RNA: ATN-RNA, intervention using interference RNA (iRNAi), use of a sequence of double-stranded RNA: ATN-RNA, a method of treating a brain tumor and a method of inhibiting a brain tumor cells which express tenascin, a kit for inhibiting cancer cell which expresses tenascin and a method for a kit preparation in a brain tumor therapy. Malignant gliomas preferentially express a number of surface markers that may be exploited as therapeutic targets, including tenascin-C, an extracellular matrix glycoprotein that is ubiquitously expressed by malignant gliomas and probably contributes to tumor cell adhesion, invasion, migration and proliferation. For tenascin-C inhibition, RNA interference intervention (iRNAi) approach have been applied.
A sequence of double-stranded ATN-RNA (dsRNA) consisting of:
A sequence of double-stranded ATN-RNA (dsRNA), consisting of:
A kit for use in inhibiting cancer cell which expresses tenascin-C, comprising reagents and components for use in treating a brain tumor, wherein the kit comprises at least one two-stranded RNA (dsRNA) sequence that is less than or equal to 200 base pairs and which comprises a fragment of the tenascin-C mRNA sequence at nucleotides 406 to 569 with a complimentary RNA sequence, wherein the fragment with the complementary RNA sequence binds to tenascin-C in a therapeutically effective amount, wherein the at least one dsRNA sequence in the kit causes a decrease in the expression of the tenascin-C gene, and inhibition of tumor growth.
Dependencies are inferred from the claim text.